Join to view full profile
3400 Civic Center BlvdPhiladelphia, PA 19104
Phone+1 215-615-6508
Fax+1 215-615-5887
Dr. Vogl is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Dan Vogl is a hematologist and medical oncologist based in Philadelphia, PA, specializing in the treatment of multiple myeloma and other plasma cell disorders. He received his medical degree from Weill Medical College of Cornell University in 2000 and completed his residency in internal medicine at Columbia Presbyterian Hospital and his fellowship in hematology and medical oncology at the University of Pennsylvania, where he also earned a Masters of Science in Clinical Epidemiology. Currently, he is an Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania. The focus of Dr. Vogl's research is on clinical trials of novel agents in relapsed and refractory myeloma and on overcoming treatment resistance to current therapies.
Education & Training
University of Pennsylvania Perelman School of MedicineMSCE, Clinical Trials Methodology, 2009
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2000 - 2003
Weill Cornell MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2023 - Present
DE State Medical License 2023 - 2027
NJ State Medical License 2022 - 2027
PA State Medical License 2003 - 2026
NY State Medical License 2001 - 2003
American Board of Internal Medicine Hematology
National Board of Physicians and Surgeons Hematology- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
Clinical Trials
- Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Sep 08
- Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
- Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
Publications & Presentations
PubMed
- Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.Gurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, Temitope Oloyede, Muhammad Bilal Abid
Transplantation and Cellular Therapy. 2026-06-16 - Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.Sandra Susanibar-Adaniya, Benjamin A Derman, Adam D Cohen, Dan T Vogl, Shambavi Richard
Blood Cancer Journal. 2026-04-28 - Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma.Heta Patel, Harper Hubbeling, Kyle Yu, Maribel Carpenter, Michael J LaRiviere
Blood Advances. 2026-02-24
Journal Articles
- Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care WorkersMatthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
Abstracts/Posters
- Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) TherapyDan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM StudyDan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple MyelomaDan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Karyopharm’s Selinexor Combination for Multiple Myeloma Unlikely to See Second-Line Use Despite Likely FDA ApprovalDecember 18th, 2020
Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual MeetingSeptember 14th, 2018
Novel Agents, Combos Excite in Multiple MyelomaNovember 28th, 2017
Grant Support
- Purinergic Receptors in MyelomaUNIVERSITY OF PENNSYLVANIA2025–2029
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
